Kowa Livalo Deal With Mitsubishi Tanabe Highlights Broader Expansion Plans
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma has agreed to market Nagoya-based drug maker Kowa's cholesterol drug Livalo (pitavastatin) through subsidiaries in Taiwan and Indonesia in a deal that shows how nimble a mid-sized Japanese firm is quickly expanding outside the home market as it gears up to enter the U.S., Canada and Europe
You may also be interested in...
Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo
Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca
Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers
Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).